Olix announced on the 12th that it has signed a total 5,300 billion won license and cooperation contract with Hansoh Pharmaceutical, a Chinese biopharmaceutical company, to research and develop asymmetric small interference (siRNA) treatment.
Based on Olix's GalNAc-asiRNA platform technology, the two companies will discover therapeutic substances for cardiovascular and metabolic diseases and develop treatments by utilizing Hanso Pharm's research and development (R&D), manufacturing and commercialization capabilities.
Hansoh Pharmaceutical has exclusive rights to the treatment only in China, and Olix has rights in all other regions.
Hansoh Pharma is China's leading anti-cancer manufacturer and an affiliate of Hangseo Pharm, the No. 1 market cap in China.
Reporter Lee Ji-sun stockmk2020@gmail.com
